The antibodies used were mouse monoclonal anti-OPN (clone OP3N, NOVOCASTRA; Leica Biosystem, Newcastle Upon Tyne, UK) and mouse monoclonal anti-MMP-9 (clone 15W2, NOVOCASTRA; Leica Biosystem, Newcastle Upon Tyne, UK), and mouse monoclonal anti-MMP-2 (clone6E3F8, ABCAM; Biotech, Life Sciences, Cambridge, MA, USA). All antibodies were optimized and validated for IHC in previous studies (Li et al., 2017 (link); Perrotta et al., 2011 (link); Sulik & Chyczewski, 2008 (link)).
Free full text: Click here